Everence Capital Management Inc. Buys New Shares in Pediatrix Medical Group, Inc. (NYSE:MD)

Everence Capital Management Inc. bought a new stake in Pediatrix Medical Group, Inc. (NYSE:MD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,880 shares of the company’s stock, valued at approximately $149,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MD. Rubric Capital Management LP boosted its position in Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after purchasing an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. boosted its position in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after purchasing an additional 455,785 shares during the period. Boston Partners boosted its position in Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares during the period. Cubist Systematic Strategies LLC boosted its position in Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after purchasing an additional 251,072 shares during the period. Finally, ClariVest Asset Management LLC acquired a new stake in shares of Pediatrix Medical Group during the second quarter worth $1,721,000. 97.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MD has been the subject of a number of research reports. UBS Group lifted their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th. Truist Financial lifted their target price on Pediatrix Medical Group from $10.00 to $13.00 and gave the stock a “hold” rating in a report on Monday, October 7th. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Finally, Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and lifted their target price for the stock from $8.00 to $14.00 in a report on Thursday, September 26th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.90.

Pediatrix Medical Group Stock Up 1.3 %

MD stock opened at $12.90 on Wednesday. The company has a market cap of $1.11 billion, a PE ratio of -4.26, a price-to-earnings-growth ratio of 1.98 and a beta of 1.56. The business has a 50-day simple moving average of $11.26 and a 200 day simple moving average of $9.20. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $12.99. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. The business had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. Pediatrix Medical Group’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.37 earnings per share. Sell-side analysts anticipate that Pediatrix Medical Group, Inc. will post 1.19 EPS for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares in the company, valued at $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares in the company, valued at $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the transaction, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,100 shares of company stock valued at $701,889 over the last quarter. 2.00% of the stock is owned by corporate insiders.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.